Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk

Hasan Mahmud Reza; Farhana Sultana; Razmin Bari; Jennifer Cole; Abdullah H.  Baqui

doi:10.1016/j.lansea.2023.100158

Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk

Hasan Mahmud Reza, Farhana Sultana, Razmin Bari, Jennifer Cole, Abdullah H. Baqui

Department of Health Studies

Research output: Contribution to journal › Article › peer-review

Abstract

Vaccine hesitancy is often assumed to be the primary cause of lower vaccination rates in low-income and middle-income countries (LMICs).1 But when vaccines are available, the vaccine acceptance rates in LMICs are as high or higher than in high-income countries (HICs), averaging around 80%.2 Despite considerable literature on vaccine inequity between the Global North and Global South, the situation persists; and this warrants the key challenges to be reiterated.

Original language	English
Article number	100158
Journal	The Lancet Regional Health - Southeast Asia
Early online date	21 Feb 2023
DOIs	https://doi.org/10.1016/j.lansea.2023.100158
Publication status	E-pub ahead of print - 21 Feb 2023

Keywords

Vaccines
Equity
Bangladesh
Pharamaceuticals
manufacturing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lansea.2023.100158Licence: CC BY

Cite this

@article{4e0a1049aab14014b4aae2903ac66134,

title = "Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk",

abstract = "Vaccine hesitancy is often assumed to be the primary cause of lower vaccination rates in low-income and middle-income countries (LMICs).1 But when vaccines are available, the vaccine acceptance rates in LMICs are as high or higher than in high-income countries (HICs), averaging around 80%.2 Despite considerable literature on vaccine inequity between the Global North and Global South, the situation persists; and this warrants the key challenges to be reiterated.",

keywords = "Vaccines, Equity, Bangladesh, Pharamaceuticals, manufacturing",

author = "Reza, {Hasan Mahmud} and Farhana Sultana and Razmin Bari and Jennifer Cole and Baqui, {Abdullah H.}",

year = "2023",

month = feb,

day = "21",

doi = "10.1016/j.lansea.2023.100158",

language = "English",

journal = "The Lancet Regional Health - Southeast Asia",

issn = "2772-3682",

publisher = "Elsevier",

}

TY - JOUR

T1 - Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk

AU - Reza, Hasan Mahmud

AU - Sultana, Farhana

AU - Bari, Razmin

AU - Cole, Jennifer

AU - Baqui, Abdullah H.

PY - 2023/2/21

Y1 - 2023/2/21

N2 - Vaccine hesitancy is often assumed to be the primary cause of lower vaccination rates in low-income and middle-income countries (LMICs).1 But when vaccines are available, the vaccine acceptance rates in LMICs are as high or higher than in high-income countries (HICs), averaging around 80%.2 Despite considerable literature on vaccine inequity between the Global North and Global South, the situation persists; and this warrants the key challenges to be reiterated.

AB - Vaccine hesitancy is often assumed to be the primary cause of lower vaccination rates in low-income and middle-income countries (LMICs).1 But when vaccines are available, the vaccine acceptance rates in LMICs are as high or higher than in high-income countries (HICs), averaging around 80%.2 Despite considerable literature on vaccine inequity between the Global North and Global South, the situation persists; and this warrants the key challenges to be reiterated.

KW - Vaccines

KW - Equity

KW - Bangladesh

KW - Pharamaceuticals

KW - manufacturing

U2 - 10.1016/j.lansea.2023.100158

DO - 10.1016/j.lansea.2023.100158

M3 - Article

SN - 2772-3682

JO - The Lancet Regional Health - Southeast Asia

JF - The Lancet Regional Health - Southeast Asia

M1 - 100158

ER -